Further analysis of correlates of protection from a phase 2a trial of the falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults

Journal of Infectious Diseases

Volumn 201, Issue 6, 2010, Pages 970-971

  Olotu, Ally Ibrahim ^a   Fegan, Gregory ^a   Bejon, Philip ^a  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE;

ANTIBODY TITER; CELLULAR IMMUNITY; CLINICAL TRIAL; HUMAN; INFECTION RISK; LETTER; MALARIA FALCIPARUM; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTIBODIES, PROTOZOAN; CD4 LYMPHOCYTE COUNT; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; REGRESSION ANALYSIS;

EID: 77749295562     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/651025     Document Type: Letter

References (3)

1. Kester KE, Cummings JF, Ofori-Anyinam O, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009;200:337-346.
2. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159:702-706.
3. Hutchings CL, Birkett AJ, Moore AC, Hill AV Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge. Infect Immun 2007; 75: 5819-5826.